Scripps Florida Scientists Confirm Key Targets of New Anti-Cancer Drug Candidates
Researchers have confirmed the ribosome assembly process as a potentially fertile new target for anti-cancer drugs by detailing the essential function of a key component in the assembly process. In experiments on human breast cancer cells, the researchers showed that CK1δ/CK1ε inhibitors no longer induce programmed cell death and prevent cancer cells from growing when Ltv1 is removed. [Press release from the Scripps Research Institute discussing online publication in The Journal of Cell Biology]
Press Release|Abstract
The Chemokine Receptor CCR7 Promotes Mammary Tumorigenesis through Amplification of Stem-Like Cells
CCR7 was found to exert its function by regulating mammary cancer stem-like cells in both murine and human tumors. In vivo experiments showed that loss of CCR7 activity either through deletion or pharmacological antagonism significantly decreased functional pools of stem-like cells in mouse primary mammary tumors, providing a mechanistic explanation for the tumor-promoting role of this chemokine receptor. [Oncogene] Abstract
The Novel Role of miRNAs for Tamoxifen Resistance in Human Breast Cancer
The authors review the miRNAs involved in regulation of tamoxifen resistance in human breast cancer and the mechanism of how the modulation of miRNAs may regulate the sensitivity of breast cancer cells to tamoxifen. They also discuss the future prospects of studies about miRNAs in regulation of tamoxifen resistance and miRNA-based therapeutics for tamoxifen resistance breast cancer patients. [Cell Mol Life Sci]
Abstract
Visit our reviews page to see a complete list of reviews in the mammary cell research field
INDUSTRY NEWS
MultiCell Immunotherapeutics and Oxis Biotech Sign Antibody-Drug Conjugate R&D, Product License and Commercialization Agreement
MultiCell Immunotherapeutics, Inc. (MCIT) announced it has signed a research & development and product license agreement with Oxis Biotech, Inc (OXIS) to create three novel antibody-drug conjugates (ADCs) containing OXIS’ lead drug candidates using MCIT’s proprietary ADC platform technology. These ADC product candidates are to be used by OXIS for the treatment of triple-negative breast cancer. [MulitCell Immunotherapeutics (PR Newswire LLC)]
Press Release
Fred Hutch Unleashes Powerful Databases with Launch of Argos
The Fred Hutchinson Cancer Research Center, in conjunction with LabKey Software, has developed and launched Argos, an application that provides the interface and analytical power that researchers and clinicians will use to search for important patterns in cancer development, progression and treatment response. [Fred Hutchinson Cancer Research Center] Press Release
Recruit Top Talent:
Reach more than 60,000 potential candidates by posting
your organization’s career opportunities on the Connexon Creative Job Board at no cost.
Have we missed an important article or publication in Mammary Cell News? Click here to submit!
_645x110.jpg)
